Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Conformational and lipid bilayer-perturbing properties of Marburg virus GP2 segments containing the fusion loop and membrane-proximal external region/transmembrane domain.

Liu N, Girvin ME, Brenowitz M, Lai JR.

Heliyon. 2019 Dec 12;5(12):e03018. doi: 10.1016/j.heliyon.2019.e03018. eCollection 2019 Dec.

2.

Peptide-Based Vaccines: Current Progress and Future Challenges.

Malonis RJ, Lai JR, Vergnolle O.

Chem Rev. 2020 Mar 25;120(6):3210-3229. doi: 10.1021/acs.chemrev.9b00472. Epub 2019 Dec 5.

3.

Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins.

Quiroz JA, Malonis RJ, Thackray LB, Cohen CA, Pallesen J, Jangra RK, Brown RS, Hofmann D, Holtsberg FW, Shulenin S, Nyakatura EK, Durnell LA, Rayannavar V, Daily JP, Ward AB, Aman MJ, Dye JM, Chandran K, Diamond MS, Kielian M, Lai JR.

PLoS Pathog. 2019 Nov 7;15(11):e1008061. doi: 10.1371/journal.ppat.1008061. eCollection 2019 Nov.

4.

Isolation of Synthetic Antibodies Against BCL-2-Associated X Protein (BAX).

Dai Z, Lai JR.

Methods Mol Biol. 2019;1877:351-357. doi: 10.1007/978-1-4939-8861-7_21.

PMID:
30536015
5.

Protocadherin-1 is essential for cell entry by New World hantaviruses.

Jangra RK, Herbert AS, Li R, Jae LT, Kleinfelter LM, Slough MM, Barker SL, Guardado-Calvo P, Román-Sosa G, Dieterle ME, Kuehne AI, Muena NA, Wirchnianski AS, Nyakatura EK, Fels JM, Ng M, Mittler E, Pan J, Bharrhan S, Wec AZ, Lai JR, Sidhu SS, Tischler ND, Rey FA, Moffat J, Brummelkamp TR, Wang Z, Dye JM, Chandran K.

Nature. 2018 Nov;563(7732):559-563. doi: 10.1038/s41586-018-0702-1. Epub 2018 Nov 21.

6.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

7.

Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.

Frei JC, Wirchnianski AS, Govero J, Vergnolle O, Dowd KA, Pierson TC, Kielian M, Girvin ME, Diamond MS, Lai JR.

J Virol. 2018 Aug 29;92(18). pii: e01023-18. doi: 10.1128/JVI.01023-18. Print 2018 Sep 15.

8.

Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.

Nyakatura EK, Zak SE, Wec AZ, Hofmann D, Shulenin S, Bakken RR, Aman MJ, Chandran K, Dye JM, Lai JR.

J Biol Chem. 2018 Apr 20;293(16):6201-6211. doi: 10.1074/jbc.RA117.001627. Epub 2018 Mar 2.

9.

Interrogation of side chain biases for oligomannose recognition by antibody 2G12 via structure-guided phage display libraries.

Lin TY, Lai JR.

Bioorg Med Chem. 2017 Oct 15;25(20):5790-5798. doi: 10.1016/j.bmc.2017.09.013. Epub 2017 Sep 15.

10.

Mechanistic and Fc requirements for inhibition of Sudan virus entry and in vivo protection by a synthetic antibody.

Hofmann D, Zak SE, Nyakatura EK, Mittler E, Bakken RR, Chandran K, Dye JM, Lai JR.

Immunol Lett. 2017 Oct;190:289-295. doi: 10.1016/j.imlet.2017.09.002. Epub 2017 Sep 8.

11.

Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.

Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, de La Vega MA, Zhu W, Bakken RR, Goodwin E, Turner HL, Jangra RK, Zeitlin L, Qiu X, Lai JR, Walker LM, Ward AB, Dye JM, Chandran K, Bornholdt ZA.

Cell. 2017 May 18;169(5):878-890.e15. doi: 10.1016/j.cell.2017.04.037.

12.

Exploring Human Antimicrobial Antibody Responses on a Single B Cell Level.

Hofmann D, Lai JR.

Clin Vaccine Immunol. 2017 May 5;24(5). pii: e00544-16. doi: 10.1128/CVI.00544-16. Print 2017 May. Review.

13.

Bispecific antibodies for viral immunotherapy.

Nyakatura EK, Soare AY, Lai JR.

Hum Vaccin Immunother. 2017 Apr 3;13(4):836-842. doi: 10.1080/21645515.2016.1251536. Epub 2016 Oct 27. Review.

14.

A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses.

Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE Jr, Aman MJ, Dye JM, Lai JR, Chandran K.

Science. 2016 Oct 21;354(6310):350-354. Epub 2016 Sep 8.

15.

Protein and Antibody Engineering by Phage Display.

Frei JC, Lai JR.

Methods Enzymol. 2016;580:45-87. doi: 10.1016/bs.mie.2016.05.005. Epub 2016 Jun 29.

16.

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.

Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ.

Cell Rep. 2016 May 17;15(7):1514-1526. doi: 10.1016/j.celrep.2016.04.026. Epub 2016 May 5.

17.

Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.

Frei JC, Nyakatura EK, Zak SE, Bakken RR, Chandran K, Dye JM, Lai JR.

Sci Rep. 2016 Jan 13;6:19193. doi: 10.1038/srep19193.

18.

Synthetic Antibodies Inhibit Bcl-2-associated X Protein (BAX) through Blockade of the N-terminal Activation Site.

Uchime O, Dai Z, Biris N, Lee D, Sidhu SS, Li S, Lai JR, Gavathiotis E.

J Biol Chem. 2016 Jan 1;291(1):89-102. doi: 10.1074/jbc.M115.680918. Epub 2015 Nov 12.

19.

Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.

Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ.

J Virol. 2015 Oct 14;90(1):266-78. doi: 10.1128/JVI.02171-15. Print 2016 Jan 1.

20.
21.

Chemical and Structural Aspects of Ebola Virus Entry Inhibitors.

Nyakatura EK, Frei JC, Lai JR.

ACS Infect Dis. 2015 Jan 9;1(1):42-52. doi: 10.1021/id500025n. Epub 2014 Dec 18.

22.

Structural and Functional Studies on the Marburg Virus GP2 Fusion Loop.

Liu N, Tao Y, Brenowitz MD, Girvin ME, Lai JR.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S146-53. doi: 10.1093/infdis/jiv030. Epub 2015 Mar 18.

23.

A switch from parallel to antiparallel strand orientation in a coiled-coil X-ray structure via two core hydrophobic mutations.

Malashkevich VN, Higgins CD, Almo SC, Lai JR.

Biopolymers. 2015 May;104(3):178-85. doi: 10.1002/bip.22631.

24.

Conditional trimerization and lytic activity of HIV-1 gp41 variants containing the membrane-associated segments.

Dai Z, Tao Y, Liu N, Brenowitz MD, Girvin ME, Lai JR.

Biochemistry. 2015 Mar 3;54(8):1589-99. doi: 10.1021/bi501376f. Epub 2015 Feb 13.

25.

Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge.

Chen G, Koellhoffer JF, Zak SE, Frei JC, Liu N, Long H, Ye W, Nagar K, Pan G, Chandran K, Dye JM, Sidhu SS, Lai JR.

ACS Chem Biol. 2014 Oct 17;9(10):2263-73. doi: 10.1021/cb5006454. Epub 2014 Aug 26.

26.

Influence of a heptad repeat stutter on the pH-dependent conformational behavior of the central coiled-coil from influenza hemagglutinin HA2.

Higgins CD, Malashkevich VN, Almo SC, Lai JR.

Proteins. 2014 Sep;82(9):2220-8. doi: 10.1002/prot.24585. Epub 2014 May 6.

27.

Structural characterization of the glycoprotein GP2 core domain from the CAS virus, a novel arenavirus-like species.

Koellhoffer JF, Dai Z, Malashkevich VN, Stenglein MD, Liu Y, Toro R, S Harrison J, Chandran K, DeRisi JL, Almo SC, Lai JR.

J Mol Biol. 2014 Apr 3;426(7):1452-68. doi: 10.1016/j.jmb.2013.12.009. Epub 2013 Dec 12.

28.

Protein engineering strategies for the development of viral vaccines and immunotherapeutics.

Koellhoffer JF, Higgins CD, Lai JR.

FEBS Lett. 2014 Jan 21;588(2):298-307. doi: 10.1016/j.febslet.2013.10.014. Epub 2013 Oct 21. Review.

29.

C-peptide inhibitors of Ebola virus glycoprotein-mediated cell entry: effects of conjugation to cholesterol and side chain-side chain crosslinking.

Higgins CD, Koellhoffer JF, Chandran K, Lai JR.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5356-60. doi: 10.1016/j.bmcl.2013.07.056. Epub 2013 Aug 2.

30.

Peptides that bind specifically to an antibody from a chronic lymphocytic leukemia clone expressing unmutated immunoglobulin variable region genes.

Liu Y, Higgins CD, Overstreet CM, Rai KR, Chiorazzi N, Lai JR.

Mol Med. 2013 Aug 28;19:245-52. doi: 10.2119/molmed.2013.00082.

31.

Role of electrostatic repulsion in controlling pH-dependent conformational changes of viral fusion proteins.

Harrison JS, Higgins CD, O'Meara MJ, Koellhoffer JF, Kuhlman BA, Lai JR.

Structure. 2013 Jul 2;21(7):1085-96. doi: 10.1016/j.str.2013.05.009. Review.

32.

Conformational properties of peptides corresponding to the ebolavirus GP2 membrane-proximal external region in the presence of micelle-forming surfactants and lipids.

Regula LK, Harris R, Wang F, Higgins CD, Koellhoffer JF, Zhao Y, Chandran K, Gao J, Girvin ME, Lai JR.

Biochemistry. 2013 May 21;52(20):3393-404. doi: 10.1021/bi400040v. Epub 2013 May 7.

33.

Side chain requirements for affinity and specificity in D5, an HIV-1 antibody derived from the VH1-69 germline segment.

Stewart A, Harrison JS, Regula LK, Lai JR.

BMC Biochem. 2013 Apr 8;14:9. doi: 10.1186/1471-2091-14-9.

34.

Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein.

Koellhoffer JF, Chen G, Sandesara RG, Bale S, Saphire EO, Chandran K, Sidhu SS, Lai JR.

Chembiochem. 2012 Nov 26;13(17):2549-57. doi: 10.1002/cbic.201200493. Epub 2012 Oct 30.

35.

Crystal structure of the Marburg virus GP2 core domain in its postfusion conformation.

Koellhoffer JF, Malashkevich VN, Harrison JS, Toro R, Bhosle RC, Chandran K, Almo SC, Lai JR.

Biochemistry. 2012 Oct 2;51(39):7665-75. doi: 10.1021/bi300976m. Epub 2012 Sep 19.

36.

Marburg virus glycoprotein GP2: pH-dependent stability of the ectodomain α-helical bundle.

Harrison JS, Koellhoffer JF, Chandran K, Lai JR.

Biochemistry. 2012 Mar 27;51(12):2515-25. doi: 10.1021/bi3000353. Epub 2012 Mar 12.

37.

A strategy for phage display selection of functional domain-exchanged immunoglobulin scaffolds with high affinity for glycan targets.

Stewart A, Liu Y, Lai JR.

J Immunol Methods. 2012 Feb 28;376(1-2):150-5. doi: 10.1016/j.jim.2011.12.008. Epub 2011 Dec 31.

38.

Synthetic Fab fragments that bind the HIV-1 gp41 heptad repeat regions.

Liu Y, Regula LK, Stewart A, Lai JR.

Biochem Biophys Res Commun. 2011 Oct 7;413(4):611-5. doi: 10.1016/j.bbrc.2011.09.012. Epub 2011 Sep 6.

39.

Designed protein mimics of the Ebola virus glycoprotein GP2 α-helical bundle: stability and pH effects.

Harrison JS, Higgins CD, Chandran K, Lai JR.

Protein Sci. 2011 Sep;20(9):1587-96. doi: 10.1002/pro.688. Epub 2011 Aug 3.

40.

Biologically inspired achromatic waveplates for visible light.

Jen YJ, Lakhtakia A, Yu CW, Lin CF, Lin MJ, Wang SH, Lai JR.

Nat Commun. 2011 Jun 21;2:363. doi: 10.1038/ncomms1358.

PMID:
21694711
41.

Inhibition of Ebola virus entry by a C-peptide targeted to endosomes.

Miller EH, Harrison JS, Radoshitzky SR, Higgins CD, Chi X, Dong L, Kuhn JH, Bavari S, Lai JR, Chandran K.

J Biol Chem. 2011 May 6;286(18):15854-61. doi: 10.1074/jbc.M110.207084. Epub 2011 Mar 16.

42.

Contribution of light chain residues to high affinity binding in an HIV-1 antibody explored by combinatorial scanning mutagenesis.

Da Silva GF, Harrison JS, Lai JR.

Biochemistry. 2010 Jul 6;49(26):5464-72. doi: 10.1021/bi100293q.

43.

Distinctive circular dichroism signature for 14-helix-bundle formation by beta-peptides.

Pomerantz WC, Grygiel TL, Lai JR, Gellman SH.

Org Lett. 2008 May 1;10(9):1799-802. doi: 10.1021/ol800622e. Epub 2008 Apr 9.

44.

Directed evolution can rapidly improve the activity of chimeric assembly-line enzymes.

Fischbach MA, Lai JR, Roche ED, Walsh CT, Liu DR.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11951-6. Epub 2007 Jul 9.

45.

Directed evolution of aryl carrier proteins in the enterobactin synthetase.

Zhou Z, Lai JR, Walsh CT.

Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11621-6. Epub 2007 Jul 2.

46.
47.

Carrier protein structure and recognition in polyketide and nonribosomal peptide biosynthesis.

Lai JR, Koglin A, Walsh CT.

Biochemistry. 2006 Dec 19;45(50):14869-79. Review.

PMID:
17154525
49.

Localized protein interaction surfaces on the EntB carrier protein revealed by combinatorial mutagenesis and selection.

Lai JR, Fischbach MA, Liu DR, Walsh CT.

J Am Chem Soc. 2006 Aug 30;128(34):11002-3.

PMID:
16925399
50.

A protein interaction surface in nonribosomal peptide synthesis mapped by combinatorial mutagenesis and selection.

Lai JR, Fischbach MA, Liu DR, Walsh CT.

Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5314-9. Epub 2006 Mar 27.

Supplemental Content

Support Center